Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S.

alvotech,-teva-reach-settlement-with-regeneron-over-eylea-biosimilar-avt06-in-us.
Chemist developing new medicine in laboratory

Luis Alvarez

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) have reached a settlement and license agreement with Regeneron Pharmaceuticals (REGN) concerning the launch of AVT06, Alvotech’s proposed biosimilar to Eylea (aflibercept) in the United States.

The settlement grants a license entry date for